JP2024518156A - ブプレノルフィンとナロキソンを含む胃内滞留システム - Google Patents
ブプレノルフィンとナロキソンを含む胃内滞留システム Download PDFInfo
- Publication number
- JP2024518156A JP2024518156A JP2023568023A JP2023568023A JP2024518156A JP 2024518156 A JP2024518156 A JP 2024518156A JP 2023568023 A JP2023568023 A JP 2023568023A JP 2023568023 A JP2023568023 A JP 2023568023A JP 2024518156 A JP2024518156 A JP 2024518156A
- Authority
- JP
- Japan
- Prior art keywords
- segment
- arms
- naloxone
- drug eluting
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184734P | 2021-05-05 | 2021-05-05 | |
| US63/184,734 | 2021-05-05 | ||
| PCT/US2022/072114 WO2022236288A1 (en) | 2021-05-05 | 2022-05-04 | Gastric residence systems comprising buprenorphine and naloxone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518156A true JP2024518156A (ja) | 2024-04-25 |
| JP2024518156A5 JP2024518156A5 (enExample) | 2025-05-09 |
Family
ID=83932451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568023A Pending JP2024518156A (ja) | 2021-05-05 | 2022-05-04 | ブプレノルフィンとナロキソンを含む胃内滞留システム |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240252483A1 (enExample) |
| EP (1) | EP4333823A4 (enExample) |
| JP (1) | JP2024518156A (enExample) |
| CN (1) | CN117615754A (enExample) |
| AU (1) | AU2022270752A1 (enExample) |
| CA (1) | CA3217611A1 (enExample) |
| IL (1) | IL308210A (enExample) |
| WO (1) | WO2022236288A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117855A1 (en) | 2018-12-03 | 2020-06-11 | Lyndra, Inc. | Stomach simulating device |
| BR112021018496A2 (pt) | 2019-03-20 | 2021-11-30 | Lyndra Therapeutics Inc | Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica |
| AU2020242062B2 (en) | 2019-03-20 | 2025-12-11 | Nortiva Bio, Inc. | Coatings for gastric residence dosage forms |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013501718A (ja) * | 2009-08-07 | 2013-01-17 | モノソル アールエックス リミテッド ライアビリティ カンパニー | 舌下及び口腔用膜組成物 |
| US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
| JP2015512924A (ja) * | 2012-04-12 | 2015-04-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | オピエート腸溶放出ビーズを含む経口フィルム |
| JP2017171687A (ja) * | 2011-09-19 | 2017-09-28 | オレクソ・アクチエボラゲット | オピオイド依存を治療するための新規乱用耐性医薬組成物 |
| JP2019532947A (ja) * | 2016-09-30 | 2019-11-14 | リンドラ,インコーポレイティド | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| JP2020523306A (ja) * | 2017-06-09 | 2020-08-06 | リンドラ,インコーポレイティド | 放出速度調節フィルムを有する胃内滞留システム |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| NZ727659A (en) * | 2014-06-11 | 2021-12-24 | Massachusetts Inst Technology | Residence structures and related methods |
| US11576859B2 (en) * | 2015-10-23 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| CN109310639A (zh) * | 2016-05-27 | 2019-02-05 | 林德拉有限公司 | 用于胃驻留系统的材料结构 |
-
2022
- 2022-05-04 WO PCT/US2022/072114 patent/WO2022236288A1/en not_active Ceased
- 2022-05-04 IL IL308210A patent/IL308210A/en unknown
- 2022-05-04 AU AU2022270752A patent/AU2022270752A1/en active Pending
- 2022-05-04 CA CA3217611A patent/CA3217611A1/en active Pending
- 2022-05-04 EP EP22799800.2A patent/EP4333823A4/en active Pending
- 2022-05-04 CN CN202280045497.1A patent/CN117615754A/zh active Pending
- 2022-05-04 US US18/289,331 patent/US20240252483A1/en active Pending
- 2022-05-04 JP JP2023568023A patent/JP2024518156A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
| JP2013501718A (ja) * | 2009-08-07 | 2013-01-17 | モノソル アールエックス リミテッド ライアビリティ カンパニー | 舌下及び口腔用膜組成物 |
| JP2017171687A (ja) * | 2011-09-19 | 2017-09-28 | オレクソ・アクチエボラゲット | オピオイド依存を治療するための新規乱用耐性医薬組成物 |
| JP2015512924A (ja) * | 2012-04-12 | 2015-04-30 | エルテーエス ローマン テラピー−ジステーメ アーゲー | オピエート腸溶放出ビーズを含む経口フィルム |
| JP2019532947A (ja) * | 2016-09-30 | 2019-11-14 | リンドラ,インコーポレイティド | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| JP2020523306A (ja) * | 2017-06-09 | 2020-08-06 | リンドラ,インコーポレイティド | 放出速度調節フィルムを有する胃内滞留システム |
Also Published As
| Publication number | Publication date |
|---|---|
| IL308210A (en) | 2024-01-01 |
| CN117615754A (zh) | 2024-02-27 |
| US20240252483A1 (en) | 2024-08-01 |
| CA3217611A1 (en) | 2022-11-10 |
| EP4333823A1 (en) | 2024-03-13 |
| AU2022270752A1 (en) | 2023-12-07 |
| EP4333823A4 (en) | 2025-04-09 |
| WO2022236288A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024518156A (ja) | ブプレノルフィンとナロキソンを含む胃内滞留システム | |
| JP2024503485A (ja) | リスペリドンを投与するための胃内滞留システム | |
| JP2025060940A (ja) | 胃内滞留システムのための材料構造物 | |
| US20250339368A1 (en) | Dosage forms for gastric retention | |
| PT2526932T (pt) | Composição farmacêutica | |
| JP2024517829A (ja) | メタドンを含む胃内滞留システム | |
| JP2010502642A (ja) | バルサルタンのための持続放出性胃滞留型経口薬物送達システム | |
| JP2025531626A (ja) | 胃内滞留システムを用いたリスペリドンの投与レジメン | |
| CA3118056A1 (en) | Systems for enteric delivery of therapeutic agents | |
| CN115003336A (zh) | 用于胃驻留系统的聚合物连接体 | |
| CN121908982A (zh) | 胃滞留系统的制备方法 | |
| CN117083059A (zh) | 用于利培酮施用的胃滞留系统 | |
| TWI837082B (zh) | 用於胃滯留系統之材料架構 | |
| CN118871091A (zh) | 用于胃滞留的剂型 | |
| WO2025199123A1 (en) | Flexible line configurations for gastric residence systems | |
| TW202500122A (zh) | 用於胃滯留系統之材料架構 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250428 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260331 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20260422 |